StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Monday. The firm set a “sell” rating on the stock.

CEL-SCI Trading Up 1.0 %

NYSE CVM opened at $0.24 on Monday. CEL-SCI has a one year low of $0.18 and a one year high of $2.39. The firm has a 50 day simple moving average of $0.30 and a 200-day simple moving average of $0.54. The firm has a market cap of $19.34 million, a price-to-earnings ratio of -0.50 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Hedge Funds Weigh In On CEL-SCI

An institutional investor recently raised its position in CEL-SCI stock. Thoroughbred Financial Services LLC boosted its holdings in CEL-SCI Co. (NYSE:CVM) by 40.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 191,661 shares of the company’s stock after purchasing an additional 54,900 shares during the quarter. Thoroughbred Financial Services LLC owned about 0.26% of CEL-SCI worth $76,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.